Phase 3
Completed N=12
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
Source: ClinicalTrials.gov NCT00648895 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Sep 2010
Primary outcomePrimary: Percentage Change From Baseline to End of Treatment for the Difference Between the Post-ischemia and Pre-ischemia Forearm Vascular Resistance (FVR).
Summary
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other biomarkers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change From Baseline to End of Treatment for the Difference Between the Post-ischemia and Pre-ischemia Forearm Vascular Resistance (FVR). |
— | — |
Eligibility Criteria
Inclusion Criteria
- Male or female, ambulatory outpatients 18-79 years old at screening
- Minimum 2-year history of Stage I/II hypertension
- Qualifying blood pressure criteria for study entry and for randomization
- Willing to adhere to the dietary compliance and undergo protocol procedures
- Have a lifestyle that will permit him/her to attend all evaluations, including those conducted on consecutive days
Exclusion Criteria
- Have any form of secondary hypertension
- Have clinically significant respiratory or cardiovascular disease
- Presence/history of coronary artery disease or peripheral vascular disease
- Have diabetes mellitus, Type I or II
- Have a history of hypersensitivity to nebivolol, metoprolol, or any beta-blocker
Data sourced from ClinicalTrials.gov (NCT00648895). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.